Background: The current Coronavirus pandemic has infected more than 15 million people worldwide and has been responsible for more than 630,000 deaths worldwide, a significant number of which has been healthcare professionals. Povidone-iodine (PVP-I) has been known as microbicidal agent since the past few decades and it has also demonstrated better anti-viral activity than other antiseptics in a few in vitro studies against other coronaviruses (SARS-CoV and MERSCoV). Povidone iodine has also been found to be a safe and effective solution to be used as a gargle or intranasally. Aim and Objectives: Through our study, we would like to propose the application of PVP-I in appropriate and safe concentration through nasal inhalation and oropharyngeal wash to limit the spread of the virus from infected patients to healthcare workers (and vice versa) and thus reduce the incidence of COVID-19. Methods: This application is to be done according to the proposed protocol, which has been devised keeping in mind the feasibility, safety and efficacy of PVP-I application. This should be used regularly in patients with a suspected or confirmed COVID-19 infection to the spread, but also by healthcare workers prior to treating such patients, or performing perioral or nasal procedures during the pandemic, regardless of the status of the patient. Patients having such procedures should also be treated with PVP-I. The total iodine exposure according to the proposed protocol has been found to be within previously recorded safe limits. Conclusion: We predict that usage of PVP-I as a personal protective equipment at the portal of entry would help decrease the rates of transmission of the infection.